The Society of Family Planning is pleased to host its Annual Meeting October 9-10, 2020. However, this year is different with the meeting occurring virtually due to the COVID-19 pandemic. The change in format means our community will not be coming together in the usual way. One of the greatest benefits of the Annual Meeting is the opportunity for family planning scholars, clinicians, and partners to gather and network. While the format will be new, the content will continue to include presentations of unpublished research and clinical practice updates as well as thought-provoking plenaries. Presenters and participants alike come from diverse disciplinary and specialty backgrounds. The Society's commitment to just and equitable abortion and contraception, informed by science means that we will continue to lift up the science generated by our membership. A total of 312 scientific abstracts were submitted this year by over 950 investigators working around the world. These abstracts were reviewed by a panel of 71 family planning experts and scored according to a rubric that included methodology, originality, significance, and potential impact. The Scientific Abstract Working Group then additionally evaluated the abstracts which scored highly on all these criteria, and chose 15 for oral presentation. An additional 83 abstracts will be presented in the poster sessions.

Four outstanding abstracts will be featured in the Spotlight on Science plenary session to showcase the breadth and depth of the extraordinary scientific work submitted this year. These multidisciplinary abstracts represent a variety of investigators using a range of rigorous study methodologies. They seek to answer important questions about contraception and abortion, ranging from the impact of Texas law on out-of-state abortions to medication abortion complications after the removal of Risk Evaluation and Mitigation Strategy in Canada. Also from an exploration of the impact of racism on the reproductive health of Black women to the effectiveness of the levonorgestrel intrauterine device (IUD) for emergency contraception.

In our first featured abstract, Raifman and colleagues provide critical data to further elucidate the impact of legislative policies on the care of patients seeking abortion. Texas House Bill 2, passed in a special legislative session after an extended filibuster by State Senator Wendy Davis, put in place a 20-week gestational age limit on abortion and led to the closure of a number of abortions clinics in the state because of increased provider and clinic regulations. This study showed us that the number of recorded out-of-state abortions by Texas residents more than doubled after implementation of the law. They also found a marked increase in abortions at later gestational ages for those women who sought care outside of the state. Data is an important tool for advocacy, and this valuable research gives us information about how HB2 negatively impacted Texas women's abortion care.

Next, Schummers and colleagues provide essential data regarding mifepristone utilization and complications after Canada removed its Risk Evaluation and Mitigation Strategy (REMS)-like restrictions in 2017. Removals of these regulations allowed physicians and advanced practice clinicians to provide telemedicine mifepristone prescriptions, community pharmacists to directly dispense mifepristone to patients, and patients to take the medication at home. This population-based study used single-payer linked health administrative data to evaluate 277,936 surgical and medical abortions in Ontario from 2012 to 2019. Deregulation of mifepristone was associated with increased utilization of medical abortion from 10.4% in 2017 to 28.7% in 2018-2019. There was no increase in abortion complications within 6 weeks, including genital tract/pelvic infection and hemorrhage, after mifepristone deregulation. Study findings provide further evidence that REMS-like restrictions for mifepristone hinder access while providing no identifiable medical benefit for patients

The third featured abstract by Treder and colleagues at Boston University explores the impact of racism on the reproductive health of US Black women. They conducted semi-structured interviews with 21 reproductive-age Black women in two large US cities to characterize how institutionalized, interpersonal, and internalized racism interact to impact reproductive health. Emerging themes from the study highlight institutionalized racism including barriers to accessing a reproductive health care provider able to meet the needs of women of color. Themes relevant to interpersonal racism included a lack of control and a sense of dehumanization, with participants reporting experiences of stereotyping and coercion around contraception decision making by providers. Internalized racism among participants resulted in disengagement with the health care system and difficulty making reproductive health decisions in the context of societal stereotypes and judgements. This study provides insight into the lived experiences of Black women in accessing reproductive healthcare which can guide future work to improve clinical practice and address structural factors of racism in women's health working towards reproductive health equity.

Lastly, Turok and colleagues investigate the effectiveness of the levonorgestrel IUD post-coital contraception. For decades, the copper IUD has been the only product that could satisfy women's needs for both immediate emergency contraception and ongoing pregnancy prevention. The levonorgestrel intrauterine system was approved for use in the US nearly 20 years ago; since then IUD use patterns have shifted to favoring the hormonal IUD over copper in a 3:1 ratio. This long-overdue trial was designed to determine whether the 52 mg levonorgestrel system is as efficacious as the copper IUD for emergency contraception. In this study conducted at six centers, the researchers recruited 655 women with at least one recent episode of unprotected intercourse and randomized them in equal proportions to one of the two intrauterine devices. They found that the levonorgestrel system was not inferior to copper in terms of preventing pregnancy in women. This study provides the best evidence to date that the levonorgestrel intrauterine system may be perfectly suitable as emergency contraception, thus expanding women's choices.
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